Cell and Gene Therapy Access Model from CMS Offers New Perspective to Value-Based Purchasing Agreements

Cell and Gene Therapy Access Model from CMS Offers New Perspective to Value-Based Purchasing Agreements

Will the involvement of a federal agency change the progress of value-based purchasing in the Medicaid program? The 2024 calendar year will provide insight into whether this intervention will expand opportunities for states and manufacturers.

Read More
 Florida Senate Passes Resolution Recognizing February 15, 2024, as Angelman Syndrome Awareness Day

Florida Senate Passes Resolution Recognizing February 15, 2024, as Angelman Syndrome Awareness Day

Artia Solutions and The Garner Group are proud to support the recognition of February 15, 2024, as Angelman Syndrome Awareness Day in the state of Florida through SR 1802, sponsored by Senator Alexis Calatayud, R-Miami Dade.

Read More
 AMP Cap Removal: What Drug Manufacturers Need to Know in 2024 and Beyond

AMP Cap Removal: What Drug Manufacturers Need to Know in 2024 and Beyond

Who will have the happier new year in 2024 – pharmaceutical manufacturers or state Medicaid programs? See what considerations will be made by each side over the next six-to-eight months to preserve finances while serving Medicaid recipients.

Read More
 2023 Crossroads Conference Recap

2023 Crossroads Conference Recap

More than 530 attendees gathered at the downtown JW Marriott in Nashville, Tennessee, on June 12-14, 2023, for the third Crossroads: An Artia Solutions Conference.

Read More
 How We Approach New York’s Unique Medicaid Programs

How We Approach New York’s Unique Medicaid Programs

Manufacturers are often intimidated when directed by New York to participate in Medicaid, due to the uniqueness of their programs. We aim to eliminate confusion in navigating these processes to resolution.

Read More
 Artia is Launching 50% of the Top 10 Most Anticipated Drug Launches of 2023

Artia is Launching 50% of the Top 10 Most Anticipated Drug Launches of 2023

Artia has been a fixture in Medicaid market access for 18 years. One of our most popular business lines is guiding drug launches in Medicaid, as evidenced by our 50% coverage of FiercePharma’s list.

Read More